VERIGRAFT receives €1.2 million to 3D print arterial grafts

VERIGRAFT, a Swedish biotechnology company, has been awarded a prestigious Eurostars grant to lead PREPPER (PREcision Printed PERsonalized Tissue Therapies) – a project developing next-generation 3D printed arterial grafts.

Together with Readily3D SA (Switzerland), RISE (Sweden), and Sahlgrenska University Hospital (Sweden), VERIGRAFT will integrate advanced 3D printing, solution-blown fiber technology, and personalized tissue engineering. The goal is to create customized vascular grafts that mimic natural arteries offering superior durability and seamless integration compared to current synthetic alternatives. The project has secured €1.2 million in funding and brings together internationally recognized experts in their respective fields to drive real innovation in regenerative medicine.

PREPPER aims to overcome the major limitations of existing grafts, such as access to human-donated material, poor integration, and high failure rates. This is expected to pave the way for a first-in-human clinical trial and future commercialization. The technology also has potential applications beyond vascular grafts.

“This Eurostars grant is a major milestone for VERIGRAFT and regenerative medicine. With PREPPER, we are accelerating the future of personalized tissue therapies,” said Dr. Raimund Strehl, CTO of VERIGRAFT. “The global vascular graft market is projected to exceed $4 billion by 2026, and PREPPER positions Europe at the forefront of 3D bioprinting and regenerative medicine.”

This project has received funding from the Eurostars-3 joint program with co-funding from the European Union’s Horizon Europe research and innovation program. Eurostars is part of the European Partnership on Innovative SMEs.